

**PATENT**

**Rec'd PCT/PTO 04 JAN 2002**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of  
**Parker et al.**

Examiner:

Art Unit:

Serial No.: **09/719,758**

Filed: **December 14, 2000**

Title: **MONOCLONAL ANTIBODIES  
DIRECTED AGAINST THE G3BP  
PROTEIN AND USES**

I hereby certify that this correspondence is being  
deposited with the United States Postal Service as  
**1st Class Express** Mail in an envelope addressed to  
Commissioner for Patents, Washington, D.C. 20231, on

**NOV. 12, 2001**

Date of Deposit

Signature

Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE  
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Commissioner for Patents

Washington, D.C. 20231

Sir:

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the enclosed pages of the "Sequence Listing" and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same; and (2) the content of the Sequence Listing and the computer readable copies required by 37 C.F.R. 1.821 (e) contain no new matter. Support for the Amendments can be found in the application as filed.

Respectfully submitted,

*Karen Krupen*

Karen I. Krupen, Reg. No. 34,647  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, New Jersey 08807-0800  
Telephone (908) 231-4658  
Telefax (908) 231-2626

Aventis Docket No. ST98017A US